Improving Public Cancer Care by Implementing Precision Medicine in Norway

PHASE2RecruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

March 30, 2040

Study Completion Date

April 30, 2045

Conditions
Cancer Metastatic
Interventions
DRUG

Atezolizumab

drugs used outside indication, based on biomarker

Trial Locations (17)

2381

RECRUITING

St Olavs Hospital, Trondheim

Unknown

NOT_YET_RECRUITING

Sykehuset Ålesund, Ålesund

RECRUITING

Haukeland universitetssykehus, Bergen

RECRUITING

Nordlandssykehuset, Bodø

RECRUITING

Vestre Viken Hospital, Drammen

RECRUITING

Førde Hospital, Førde

RECRUITING

Sykehuset Innlandet, Hamar

NOT_YET_RECRUITING

Helse Fonna, Haugesund

RECRUITING

Sørlandet sykehus, Kristiansand

NOT_YET_RECRUITING

Sykehuset Levanger, Levanger

RECRUITING

Ahus, Oslo

RECRUITING

Sykehuset Telemark, Skien

RECRUITING

Stavanger universitetssykehus, Stavanger

RECRUITING

Universitetssykehuset i Nord-Norge, Tromsø

NOT_YET_RECRUITING

Sykehuset Vestfold, Tønsberg

RECRUITING

Sykehuset Østfold Kalnes, Fredrikstad

0379

RECRUITING

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Haukeland University Hospital

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

collaborator

University Hospital, Akershus

OTHER

collaborator

Vestre Viken Hospital Trust

OTHER

collaborator

Hospital of Southern Norway Trust

OTHER

collaborator

Ostfold Hospital Trust

OTHER

collaborator

The Hospital of Vestfold

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

Nordlandssykehuset HF

OTHER

collaborator

Sykehuset Innlandet HF

OTHER

collaborator

Helse Forde

OTHER

collaborator

Helse Fonna

OTHER

collaborator

Helse Nord-Trøndelag HF

OTHER

collaborator

Helse Møre og Romsdal HF

OTHER_GOV

collaborator

Sykehuset Telemark

OTHER_GOV

collaborator

Lovisenberg Diakonale Hospital

OTHER

lead

Oslo University Hospital

OTHER